Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A large meta-analysis confirms that human metapneumovirus (HMPV) carries serious risks — nearly half of confirmed cases required hospitalization, and in-hospital mortality reached 6% among adults. Researchers analyzed 94 studies covering ~26,000 patients across multiple continents. The findings underscore the urgent need to strengthen HMPV surveillance and standardize outcome reporting globally.
HMPV has long been overshadowed by influenza and RSV, but a sweeping new meta-analysis suggests it deserves far more attention. Researchers analyzed 94 observational studies covering roughly 26,000 patients with laboratory-confirmed HMPV infection from across North America, Europe, Asia, Africa, and Latin America — spanning data from 1976 to 2026.
The results paint a sobering picture: nearly half of all confirmed HMPV cases required hospitalization, and among those admitted, outcomes were frequently severe. Adults fared the worst, with an in-hospital mortality rate of 6%. The authors are calling for stronger surveillance systems and more standardized reporting to better understand who is most at risk.
By the Numbers:
Why it matters: HMPV lacks an approved vaccine or targeted antiviral therapy, yet this analysis shows it carries a significant burden of severe illness and death — particularly in adults. Better surveillance and prospective data collection could pave the way for improved risk stratification and, eventually, targeted interventions.
